To the G20: incentivising antibacterial research and development

被引：23

作者：

Ardal, Christine ^{[1
]}

Baraldi, Enrico ^{[2
]}

Ciabuschi, Francesco ^{[3
]}

Outterson, Kevin ^{[4
,5
]}

Rex, John H. ^{[5
]}

Piddock, Laura J. V. ^{[6
]}

Findlay, David ^{[7
]}

机构：

[1] Norwegian Inst Publ Hlth, Div Infect Control & Environm Hlth, N-0403 Oslo, Norway

[2] Uppsala Univ, Dept Engn Sci Ind Engn & Management, Uppsala, Sweden

[3] Uppsala Univ, Dept Business Studies, Uppsala, Sweden

[4] Boston Univ, Sch Law, Boston, MA 02215 USA

[5] CARB X, Boston, MA USA

[6] Univ Birmingham, Inst Microbiol & Infect, Birmingham, W Midlands, England

[7] GlaxoSmithKline, London, England

来源：

基金：

英国惠康基金;

关键词：

RESISTANCE;

D O I：

10.1016/S1473-3099(17)30404-8

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：799 / 801

页数：3

共 9 条

[1] [Anonymous], ANT CURR CLIN DEV
[2] [Anonymous], 2017, BREAK THROUGH WALL C
[3] [Anonymous], 2016, G20 LEAD COMM HANGZH
[4] O'Neill, 2016, TACKLING DRUGRESISTA
[5] Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, David J.
Gwynn, Michael N.
Holmes, David J.
Pompliano, David L.
[J]. NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (01) : 29 - 40
[6] Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach
Rex, John H.
Outterson, Kevin
[J]. LANCET INFECTIOUS DISEASES, 2016, 16 (04) : 500 - 505
[7] Plasmid-mediated colistin resistance (mcr-1 gene): three months later, the story unfolds
Skov, R. L.
Monnet, D. L.
[J]. EUROSURVEILLANCE, 2016, 21 (09): : 2 - 7
[8] Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study
Teillant, Aude
Gandra, Sumanth
Barter, Devra
Morgan, Daniel J.
Laxminarayan, Ramanan
[J]. LANCET INFECTIOUS DISEASES, 2015, 15 (12) : 1429 - 1437
[9] World Health Organization, 2017, Global priority list of antibiotic-resistant bacteria